Resilience is a private company operating at the intersection of advanced biomanufacturing and cyber risk solutions, and this is a weekly summary of notable news about the firm. The company highlighted its role in next-generation therapeutic manufacturing while also publishing new data-driven insights into cybersecurity risks facing industrial clients.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
During the week, Resilience emphasized its participation as a supporting partner and exhibitor at MassBio’s R&D Reimagined: Advanced Modalities conference in Boston on May 11. Company representatives plan to meet biotech and pharma R&D leaders focused on cell and gene therapies, RNA-based treatments, and other advanced platforms.
Across its communications, Resilience underscored capabilities in sterile fill-finish operations, including prefilled syringes and vial-based biomanufacturing for complex biologics. By aligning its presence with major industry gatherings such as MassBio, TIDES, and ASGCT, the firm appears to be deepening engagement with innovators in high-growth therapeutic areas.
These activities could support future contract manufacturing opportunities as Resilience positions itself as a partner for advanced-modality programs. Strengthening visibility and relationships with prospective biotech and pharma clients may reinforce the company’s role in specialized biomanufacturing services and its long-term revenue pipeline.
In a separate development, Resilience released a report titled “The State of Cybersecurity in Manufacturing,” drawing on proprietary insurance claims data. The analysis found that ransomware accounts for only 12% of incident volume in its manufacturing portfolio but drives more than 90% of total incurred losses.
A single BlackCat ransomware incident linked to misconfigured multi-factor authentication emerged as the costliest case, with MFA failures representing roughly 26% of portfolio losses. The company identified key mitigations, including auditing MFA deployments, tightening vulnerability management for internet-facing systems, and improving controls over financial transfers.
Resilience also recommended extending security requirements to critical vendors and supply chain partners to reduce systemic exposure. Leadership, including CEO Vishaal “V8” Hariprasad and Risk Operations Center head Jud Dressler, stressed that these measures are relatively straightforward yet deliver substantial risk reduction.
By pairing cyber insurance with software and expert services, Resilience seeks to position itself as a data-driven risk partner for large and mid-market organizations in the U.S., U.K., Canada, and Europe. Overall, the week showcased the company’s dual focus on scaling its advanced biomanufacturing footprint and sharpening its cyber risk insights for industrial clients.